THE RESTORE ISSUE

AUGUST 2022
As we make our way through the month of August, before the seasons change once again, it is time to reflect and restore ourselves. We invite you to close your eyes, take three deep breaths and enjoy our month’s offerings.

We’re excited to share that our organization has earned a 2022 Platinum Seal of Transparency with Candid! Now, you can support our work with trust and confidence by viewing our Nonprofit Profile Here:

TIGERLILY FOUNDATION - GUIDESTAR PROFILE

Platinum Transparency 2022
Candid.

HER2+ Empower Listening Summit – Part 3: HER Pathway Forward

Join us on for our Final Conversation in the HER2+ Empower Listening Series on Thursday, August 18 2022, at 1 pm - 2 pm ET as we explore the “HER 2+ Way Forward” with ANGEL Advocates and a Clinical Nurse Educator, Marnae Colston-Jackson. Come on this journey as we create a safe space to share about our emotional wellbeing and the role of spirituality while navigating HER 2+.

CLICK HERE TO REGISTER!
Pure Cat Monthly Schedule

Tigerlily’s Pure Cat Initiative is an online wellness platform that is open to all. We are dedicated to healing through movement, meditation, fitness, yoga, prayer and more. Our dedicated instructors welcome all skill levels and abilities, so whether you need a relaxing sound bath at the end of a long week, or a mid-week energy boost to get your blood flowing, there’s something for everyone.

CLICK HERE TO SIGN UP FOR OUR PURE CAT CLASSES!

#InclusionPledge Race Alliance partner spotlight

Patient Empowerment Network (A Tigerlily Foundation RACE Alliance partner and #InclusionPledge signee) is hosting a CLL webinar on Tuesday, August 23rd entitled “Participating in a Clinical Trial: What You Need to Know.” In this webinar, Dr. Pauline Funchain, cancer expert and researcher, will share insights about what to expect when joining a clinical trial, including patient safety and tips for finding a trial that’s right for you. Patient advocate and colorectal cancer survivor, Cindi Terwoord, will also join to share her experience and her advice for other people with cancer.
Thank you to BAYER for signing the #InclusionPledge and working with us to help end disparities in healthcare!

Brain Fog Research with Inova

Inova Life with Cancer (A Tigerlily Foundation #InclusionPledge member and RACE Alliance Partner) has a new study on brain fog. To learn more or participate in this research use the QR code below, or CLICK HERE!

Are you curious about how to determine your #InclusionPledge Commitments?

We are unveiling a series of guides to help you and your organization determine your starting point.

Industry one Pager release Dates
August 5: Advocacy Guide to the Inclusion Pledge
August 12: Clinician Guide to the Inclusion Pledge
August 19: College Guide to the Inclusion Pledge
August 26: Diagnostics Guide to the Inclusion Pledge
August 31: Faith Based Guide to the Inclusion Pledge
Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act (H.R. 8185/S. 4440)

The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is a critical safety-net program that provides breast and cervical cancer education, screening, and diagnostic services for underserved populations who are low-income, uninsured and underinsured who do not qualify for Medicaid. The program has a proven record of cancer detection and provides public education, outreach, patient navigation, and care coordination to increase breast cancer screening rates and reach these underserved populations. The Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act reauthorizes and modernizes the NBCCEDP by allowing:

• expansion of services for individuals at increased risk of breast cancer
• a greater emphasis on implementing innovative evidence-based interventions, and
• proactive outreach to underserved communities through media, peer educators, and patient navigators.

Take action with us and let your representatives know you want their support today
Access to screening is even more important as many people delayed or missed annual screenings due to the COVID-19 pandemic, likely resulting in more advanced cancers and increased cancer deaths; and new populations may need assistance to access basic cancer screenings due to the pandemic-related financial crisis. NBCCEDP is one of the only programs that serve these under-resourced, underserved communities throughout the country, as well as populations facing high disparities and morbidities from breast cancer. This piece of legislation is an important step toward ensuring that more women receive access to essential screening services before it is too late.

In addition, the reauthorization of the NBCCEDP and increased funding would allow for triple-negative breast cancer (TNBC) specific support, including education and diagnosis strategies in existing breast cancer screening, diagnosis, and linkage to health care programs. **TNBC is an aggressive form of breast cancer that disproportionately impacts Black, Hispanic, and younger women and is often diagnosed at later stages of the disease with a poor prognosis.** This funding, along with $3M allocated to expand awareness and prevention efforts for Breast Cancer Awareness for Young Women in connection with the goals of the Cancer Moonshot, will help address the significant TNBC inequities.

CLICK HERE FOR THE SCREENS ACT AND TNBC FACTSHEET.

**Increasing Access to Bone Health Screening for Breast Cancer Patients**

Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act (H.R. 3517/S. 1943)

While treatments provide patients with potentially life-saving options, many common breast cancer treatments take a toll on bone health. For this reason, it is especially important for breast cancer patients to have access to bone health and osteoporosis screening. However, for most, becoming aware of the onset of osteoporosis occurs either by an accidental fall and breaking a bone or by having a DEXA (dual energy x-ray absorptiometry) examination. This is even more true for Patients of Color, as racial and ethnic disparities exist for screening, diagnosis, and treatment of osteoporosis as they do for breast cancer. Further adding to these disparities, since 2007, Medicare has cut reimbursement rates for DEXA screening by 72% which has resulted in nearly half of DEXA office providers discontinuing these services. Currently, DEXA testing is reimbursed at $39 while a decade ago DEXA was reimbursed at $139. These cuts have left physicians unable to continue providing DEXA testing. These cuts have led to a decline in testing and an increase in barriers to access osteoporosis testing, most especially for those living in underserved and/or rural areas, widening the already existing disparities facing breast cancer patients of color. H.R. 3517/S. 1943 would set the reimbursement rate back to an appropriate level.

The Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act is bipartisan legislation and will support better outcomes for breast cancer patients, take a step towards health equity, and lower costs for our health care system.

For additional information, see our fact sheet here.

Please consider sharing this issue with your friends, family and networks by posting on social media!
2022 Qualitative Project

Are you interested in sharing part of your breast cancer experience?

The Tigerlily Foundation is partnering with Dr. Ruby Mendenhall from the University of Illinois at Urbana-Champaign for an interview-based study to examine how Black women navigate body image and self-confidence with the purpose of improving the quality of life of breast cancer survivors. The research team comprises of Dr. Mendenhall, Research Scientist Florence Adibu and Virginia Leach, TLF Manager of Research and Writing. Virginia will host four, optional Information Sessions to learn more about the project and how you can participate. Register to attend an Information Session by clicking this [link](#). If you have any questions about the research project, please contact Virginia at virginia@tigerlilyfoundation.org.

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

The U.S. Food and Drug Administration approved an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.

CLICK HERE TO READ THE FULL ARTICLE!

**FIRST OPINION**

Triple-negative breast cancer highlights the need to act against health inequities

By Maimah Kamo | Aug 8, 2022

Tigerlily in the Media

Black women are 41% more likely to die of breast cancer than white women. Congress must increase funds to address the significant inequities among under supported women with breast cancer.

READ FULL ARTICLE HERE